
-
BioLineRx NASDAQ:BLRX
Location: Modi'in Technology Park, Modiin, 7177871, Israel | Website: http://www.biolinerx.com/ | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.308B
Cash
29.17M
Avg Qtr Burn
-7.568M
Short % of Float
0.01%
Insider Ownership
4.68%
Institutional Own.
1.51%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
APHEXDA®(Motixafortide )(BL-8040) (CXCR4 antagonist) Details Stem cell mobilization, Multiple myeloma | Approved Quarterly sales | |
Motixafortide (BL-8040) w/ zimberelimab Details Pancreatic cancer, Cancer, Solid tumor/s | Phase 2b Initiation | |
Motixafortide (BL-8040) w/ cemiplimab Details Cancer, Solid tumor/s, Pancreatic cancer | Phase 2 Data readout | |
Motixafortide (BL-8040) Details Blood disorder, Sickle cell disease | Phase 1 Data readout | |
Motixafortide (BL-8040) +/- natalizumab Details Sickle cell disease, Blood disorder | Phase 1 Data readout | |
AGI-134 Details Solid tumor/s, Cancer | Failed Discontinued | |
Motixafortide (BL-8040) (CXCR4 antagonist) Details Acute myeloid leukemia | Failed Discontinued | |
Motixafortide (BL-8040) (CXCR4 antagonist) Details Pancreatic cancer, Solid tumor/s, Cancer | Failed Discontinued |